Breast Cancer Clinical Trial
Women with primary breast cancer may benefit from participating in supports groups as they
cope with treatment and the psychological challenges of survivorship. Studies have
documented that these women benefit from support groups run in a university setting;
however, no one has documented that they benefit from community cancer support groups. Many
community cancer support groups exist and provide service to a large number of women with
breast cancer. It is important to know if these groups are providing comparable service to
well researched support groups. We conducted this study as the first randomized study of
community compared to university-style support groups. Women had a 50/50 chance of being
assigned to either a community or a university style support group based on a coin flip.
This study took place in two sites The Wellness Community East Bay (Walnut Creek) and San
Francisco. Two community groups were studied.
i) This study evaluated the strengths and weaknesses of two community-based support group
interventions for breast cancer patients [The Wellness (TWC) and Cancer Support (CSC)
Communities, in the San Francisco area]. We compared them with a type of therapy developed
in the university setting (Stanford's Supportive-Expressive group therapy), studied which
aspects are most effective, and who benefits the most. We compared these women on change in
emotional distress, means of coping with cancer, and social and family support. In addition,
change in physiological response to stress was measured using saliva samples.
ii) We were able to achieve recruitment for 6 of 8 groups proposed. We randomized 72 women
in blocks of 12 taking consecutive women per site until we accrued 12 for each group. Of
those, 61 women actually attended groups, of those 46 women to date completed at least one
follow-up and were available for analysis for this report. We screened 108 women, 16 who
were screened out on initial phone contact, 20 women began to go through our baseline
interviews and assessments and either decided not to enroll or dropped out before we could
compose a group for the second S.F. randomization. Our final two follow-up assessments for
our final group in the East Bay are being conducted right now (8 month) and will be
conducted in October, 2002 (12 month) so they are not available for assay or analysis for
this final report.
iii) We examined 5 outcome variables for this report and found that women participating in
the community groups changed at about the same level over the 4 months of group therapy as
the women in the Stanford groups. This was true for depression symptoms, trauma symptoms,
social support, self-efficacy, and post-traumatic-growth. These analyses are preliminary
until we complete our final follow-up assessments. It is encouraging for the community
groups that women benefited at the same rate as they did in the well-researched Stanford
groups. Conclusions for this study are somewhat limited because we could not complete the
recruitment of our entire sample. However, there is every reason to suppose that community
groups are as effective at serving women with primary breast cancer as Stanford's groups
though they are based on very different ideas of therapy. It is important to note that all
of these groups were led by therapists, and that we may have found other results if the
groups had been led by peers or other types of professionals. This study reduces the human
and economic cost of breast cancer in California by validating community groups usually
offered free to women with breast cancer.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |